Please assess the completion status of the following clinical trial:

Trial Title: Study of Brimonidine Tartrate Nanoemulsion Eye Drops in Patients With Ocular Graft-vs-Host Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men or women ≥ 18 years of age~* Diagnosis of definite oGVHD using the International Chronic Ocular GVHD Consensus Group Revised Diagnostic criteria in at least one eye.~* Ocular Discomfort score ≥ 3~* Validated Bulbar Redness score ≥ 40 in both eyes~* Subjects who are capable and willing to provide informed consent and follow study instructions~* Intraocular pressure (IOP) ≥ 5 mmHg and ≤22 mmHg in each eye~* Women who are not pregnant or lactating or post-menopausal or have undergone a sterilization procedure~Exclusion Criteria:~* Allergic to brimonidine or any similar products, or excipients of brimonidine~* Currently receiving any brimonidine or other treatment for glaucoma~* Receiving or have received any investigational drug or device within 30 days of screening~* Current use of contact lenses 14 days prior to screening~* Active ocular infection or ocular allergies~* Any history of eyelid surgery or ocular surgery within the past 3 months~* Corneal epithelial defect larger than 1 mm (squared) in either eye~* Received corticosteroid-containing eye drops within 14 days prior to screening or planned use during the study~* Any change in corticosteroid-containing eye drops, systemic corticosteroids/immunosuppressives, topical ocular antibiotics, cyclosporine ophthalmic emulsion 0.05% (Restasis®), cyclosporine ophthalmic solution 0.09% (Cequa®) or lifitegrast ophthalmic solution 5% (Xiidra®), or autologous serum tears within 30 days prior to screening or planned change during the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- OCU-300 (Type: EXPERIMENTAL): Brimonidine Tartrate Nanoemulsion Eye Drops 0.18% given 2 times a day for 12 weeks.
- Placebos (Type: PLACEBO_COMPARATOR): Placebo - Ophthalmic buffered saline Eye Drops given 2 times a day for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).